Non Small Cell Lung Cancer (NSCLC)

Stage IV/Metastatic - 2nd Line - Immunotherapy

- No Prior Therapy With PD-1/PD-L1
- On anti PD-1/anti PD-L1 with response, stable disease or modest progression
- Failed Therapy PD-L1

**THOR0006**
Phase II/III of Nivolumab with Vorolanib in Refractory Thoracic Tumors
PI: Wakelee NCIN

**LUN0168**
Phase II
Radical-Dose RT with Anti-PD-1/ Anti-PD-L1 Immunotherapy in Non-Small Cell Lung Cancer
PI: Gensheimer Stanford

**THOR0006**
Phase II/III of Nivolumab with Vorolanib in Refractory Thoracic Tumors
PI: Wakelee NCTN

**LUN017**
Phase III
Atezolizumab +/- Cabozantinib vs Docetaxel Monotherapy in Metastatic Non-Small Cell Lung Cancer
PI: Neal Sponsor: Hoffman La Roche

**LUN0107**
Phase Ib/II
Grapiprant +/- Pembrolizumab in Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma
PI: Wakelee Arvs Therapeutics

**ECOG ACRIN-EAS191**
Phase II
Cabozantinib +/- Nivolumab vs Standard Chemotherapy in Previously Treated Non-Squamous NSCLC
PI: Neal Pending

**KEY**
- Optional Path
- Extension Study
- Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu